Evaluation of Safety and Efficacy of fixed dose combination of L-Ornithine-L-Aspartate 150 mg, Pancreatin IP 100mg enteric coated tablets as supportive and maintenance therapy in hepatitis: A Phase IV, Prospective, Open Label, Multi-centric, Single Arm, Clinical Study. - Hepamerz
Secondary Prophylaxis of hepatic encephalopathy in cirrhosis:A double Blind randomized controlled trial of L-Ornithine L-Aspartate (LOLA) versus placebo - LOLA
100 项与 Win-Medicare Pvt Ltd. 相关的临床结果
0 项与 Win-Medicare Pvt Ltd. 相关的专利（医药）
100 项与 Win-Medicare Pvt Ltd. 相关的药物交易
100 项与 Win-Medicare Pvt Ltd. 相关的转化医学
